+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies



Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies



Journal of Family Practice 59(9 Suppl 1): S20-S27



The overall safety profiles of GLP-1 agonists and DPP-4 inhibitors are favorable, with a low incidence of hypoglycemia. This attribute, along with their weight and cardiovascular benefits, particularly with the GLP-1 agonists, make them appropriate choices in our 3 patient cases. Ongoing safety investigations with GLP-1 agonists and DPP-4 inhibitors will provide further clarity to the complete safety profiles of these agents.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052665003

Download citation: RISBibTeXText

PMID: 20824236


Related references

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S10-S19, 2010

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovascular and Hematological Agents in Medicinal Chemistry 10(4): 276-288, 2012

Incretin Pharmacology A Review of the Incretin Effect and Current Incretin-Based Therapies. 2012

Distinguishing among incretin-based therapies. Introduction. Journal of Family Practice 59(9 Suppl 1): S3-S4, 2010

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and Dpp-4 Inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models. Journal of Pathology 238(2): 345-358, 2016

Distinguishing among incretin-based therapies. Patient education and self-management. Journal of Family Practice 59(9 Suppl 1): S28-S30, 2010

Safety of incretin-based therapies for type 2 diabetes. Medical Journal of Australia 195(6): 312-313, 2011

The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovascular Diabetology 12: 130, 2013

The safety of incretin-based therapies--review of the scientific evidence. Journal of Clinical Endocrinology and Metabolism 96(7): 2027-2031, 2011

Incretin and incretin-based therapies. Nihon Rinsho. Japanese Journal of Clinical Medicine 68(5): 931-942, 2010

A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology and Metabolism 11(2): 217-232, 2016

Efficacy and safety of incretin based therapies: clinical trial data. Journal of the American Pharmacists Association 49(Suppl. 1): S30-S40, 2009